Reuters: Actavis has approached Allergan about a deal; Bayer completes Dihon pickup;

Allergan HQ

@FiercePharma: Tops this weekend: Express Scripts ready to favor AbbVie hep C prospect--provided it undercuts. Article | Follow @FiercePharma

@EricPFierce: The revamp continues at Takeda, as does its financial struggles. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Express Scripts ready to favor AbbVie hep C prospect--provided it undercuts Gilead. Story | Follow @CarlyHFierce

> Allergan ($AGN) says it's been approached about a deal by a company other than pursuer Valeant ($VRX), and Reuters' sources say that company is Actavis ($ACT). Report

> Bayer has completed its pickup of China's Dihon Pharmaceutical Group, an OTC company it agreed to acquire in February. Report

> Planning officials are recommending approval of a scheme for GlaxoSmithKline's ($GSK) £25 million investment in in its Montrose, U.K., API plant. Report

> Pfizer ($PFE) EVP Anthony Maddaluna last week unloaded 2,425 shares of the company's stock. Report

Medical Device News

@FierceMedDev: ICYMI: Diagnostic companies homing on on rapid mobile tests to quell Ebola outbreak. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: UPDATED: Medtronic discloses new corporate structure upon Covidien deal close. Story | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific set to face first federal trials over transvaginal mesh products. Reuters article | Follow @EmilyWFierce

> With new fund, Rock Health to invest more money in fewer companies. Story

> Boston Scientific faces first two federal trials for transvaginal mesh devices. Article

Biotech News

@FierceBiotech: Nymox blasted as lead drug flops in twin PhIII enlarged prostate studies. News | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers beefs up fibrosis pipeline with $444M option deal. Report | Follow @JohnCFierce

@DamianFierce: $BMY gets into IPF with Galecto (and Magnus Persson, its fantastically named chairman) in a deal worth up to $444M. Release | Follow @DamianFierce

@EmilyMFierce: The planet's deadliest infectious diseases, by country. More via Salon | Follow @EmilyMFierce

> Geron shares rocket up after FDA takes the cuffs off its lead drug. Story

> $6B Covance buyout puts LabCorp in the CRO biz. Report

> Takeda drops a $750M schizophrenia drug pact with Intra-Cellular. Item

CRO News

> PRA raises the stakes, eyeing $400M in a blockbuster IPO. More

> CRO Paragon raises $13M to expand its footprint. Story

> LabCorp is buying Covance for $5.6B to cut in on the CRO boom. News

> Timely deals boost Charles River's balance sheet. Story

> Quintiles posts another $1B quarter and dials up its expectations. Report

Biotech IT News

> Venter makes new hires at Synthetic Genomics and Human Longevity. Item

> Cleveland Clinic teams with IBM to use Watson in genomics cancer research. Report

> Report: GSK, J&J, Merck and Sanofi have made mobile app breakthroughs. More

> Novo Nordisk pushes back date of IT IPO decision to 2015. Story

> Boehringer picks IDBS system in consolidation of ELN. Article

Animal Health News

> IDEXX follows positive earnings with acquisition of Animana. Item

> Advaxis sees encouraging results for immuno-oncology treatment in dogs with bone cancer. Report

> Analysts to Heska: Why has strong performance been overlooked? Article

> Jaguar Animal Health trims IPO target number by 26%. More

> Possible threat to strong launch of Merial's anti-flea pill NexGard adds to Sanofi's woes. Story

And Finally... Amid a lack of competition for snakebite drugs that's kept prices around $50,000 per treatment, an alternative now may hit the market as soon as 2018--10 years earlier than planned--thanks to a new licensing deal. Report